MAP2K7 and RASopathy: In several of the mouse or other model system studies described above, a MEK inhibitor was used as a prenatal preventative therapy or postnatal treatment, raising the possibility that MEK inhibitors may be effective in the treatment of non-NF1 RASopathies.